Wednesday, April 2, 2025

HOYA Group Company, PENTAX of America, Inc. and MAGENTIQ EYE Ltd. Announce their Intention to Form a Distribution Partnership for the U.S Market

Related stories

Hacking the Hackers: How GenAI is Predicting and Preventing Cyber Attacks

In the high-stakes arena of cybersecurity, the rules of...

Veltris Acquires BPK to Boost AI & Digital in Healthcare

Veltris, a digital product engineering services provider backed by...

Accenture & Schaeffler Advance Industrial Humanoid Robots

Accenture has joined forces with Schaeffler AG to reshape...

EDGNEX Data Centers partners with Hyperco

The acquisition is expected to further strengthen the expansion...

Chef Robotics Raises $43M Series A to Scale AI Robotics

Chef Robotics, a leader in AI-powered robotic systems for...
spot_imgspot_img

HOYA Group Company, PENTAX of America, Inc. (PENTAX Medical) and MAGENTIQ-EYE Ltd., an AI medical device company, announced their intention to form a partnership in the field of AI in Gastroenterology and to examine further collaboration and strategic partnerships.

Pending field trials and customer demonstrations to be conducted over the next several months, the companies expect to formalize an agreement as a first step in this partnership, by which PENTAX Medical will distribute the MAGENTIQ-COLO™ AI-assisted lesion detection device in the U.S.A. beginning October 1st, 2024. The system will be demonstrated at the upcoming Digestive Disease Week (DDW) in Washington D.C., U.S.A.

MAGENTIQ-COLO™ is a cutting-edge system for the detection of gastrointestinal lesions in colonoscopies. Successfully validated in an international multicenter, randomized, controlled trial (RCT) with 950 enrolled patients at 10 hospitals in EuropeUnited States and Israel, its outstanding diagnostic capabilities are setting new standards in endoscopic AI.

Also Read: ScribeAmerica Continues to Evolve Speke AI Clinical Documentation Offering

“We are excited to bring the MAGENTIQ-COLO™ device to the GI community in the U.S. Together with PENTAX Medical’s product portfolio, we are confident to provide a smart solution in colonoscopy and contribute further to colorectal cancer prevention”, says David Harrison, President PENTAX of America, Inc.

“Partnering with PENTAX Medical is an important milestone for us, as it opens new opportunities to introduce our game changing product to the U.S. market, benefiting doctors and their patients and saving more lives”, says Dror Zur, Founder & CEO of MAGENTIQ-EYE.

Source: PRNewsWire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img